Total operating revenue increased by 33.3% to RON1.42 billion, compared with RON1.06 billion in the previous year. Operating expenses grew by 33%, to RON1.40 billion, Ropharma said its financial report.
The company is valued by investors on the Bucharest Stock Exchange at RON107 million, after its shares have gained 31% in the past year. The largest shareholders are Progresso Investments (31.2%), ADD Pharmaceuticals (17.8%), and Rimia Investments Limited (14.1%), all of which based in Cyprus.
(English version by Loredana Fratila-Cristescu)